Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023 16:05 ET
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast
October 24, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer...
IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester
September 21, 2023 07:00 ET
|
Research Nester
New York, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is estimated to grow at a CAGR of ~8% over the forecast period. The market is...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
September 20, 2023 04:43 ET
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
Interchangeable Biosimilars Market revenue to hit USD 65 Billion by 2035, says Research Nester
September 11, 2023 07:00 ET
|
Research Nester
New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- The global Interchangeable Biosimilars market size is slated to expand at ~ 20 % CAGR between 2023 and 2035. The market is poised to garner a revenue of...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023 07:05 ET
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Global Gastrointestinal Partnering Analysis Report 2023: Deal Trends, Players and Financials for Over 480 Deals Signed Since 2016 by the World's Leading Life Science Companies
May 31, 2023 03:13 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.Global...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
May 10, 2023 16:05 ET
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 10, 2023 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...